Roche Holding AG (OTCMKTS:RHHBY) Receives Consensus Recommendation of “Hold” from Analysts

Roche Holding AG (OTCMKTS:RHHBY) has been assigned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $51.50.

A number of analysts recently weighed in on RHHBY shares. TD Cowen reissued a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. Wolfe Research reissued an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price on the stock in a research note on Friday, April 24th. Finally, Argus raised shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th.

Roche Stock Performance

OTCMKTS:RHHBY opened at $50.23 on Wednesday. The firm’s 50-day moving average is $50.97 and its 200-day moving average is $52.39. Roche has a 52-week low of $37.51 and a 52-week high of $60.85. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38.

Institutional Trading of Roche

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RHHBY. S&CO Inc. increased its stake in Roche by 1.9% in the third quarter. S&CO Inc. now owns 52,154 shares of the company’s stock valued at $2,129,000 after acquiring an additional 955 shares during the period. PNC Financial Services Group Inc. boosted its position in Roche by 23.0% in the third quarter. PNC Financial Services Group Inc. now owns 18,799 shares of the company’s stock valued at $786,000 after buying an additional 3,513 shares in the last quarter. Vestmark Advisory Solutions Inc. acquired a new position in Roche in the third quarter valued at about $597,000. Curio Wealth LLC acquired a new position in Roche in the third quarter valued at about $25,000. Finally, Douglass Winthrop Advisors LLC acquired a new position in Roche in the third quarter valued at about $201,000.

Roche News Summary

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Roche entered a global collaboration with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an investigational BTK degrader for blood cancers with potential expansion into immunology and neurology. The deal includes a $700 million upfront payment, a possible total value of up to $2.3 billion, and gives Roche another shot at strengthening its oncology pipeline. Article Title
• Positive Sentiment: The collaboration was also framed as a strategic fit with Roche’s existing B-cell therapy and commercialization capabilities, which could support future growth if bexobrutideg succeeds in clinical development. Article Title
• Neutral Sentiment: Roche said it is keeping its planned €600 million investment in Germany despite broader industry concerns and some competitors scaling back spending there. This supports its long-term manufacturing and European footprint, but the immediate stock impact is likely limited. Article Title
• Negative Sentiment: No major negative company-specific development was reported in the latest batch of news; however, investors may be watching execution risk around the large Nurix deal and the cost of continued pipeline investment. Article Title

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.